Clinical Trial to Assess Influence of MyCyFAPP Use on GI Related QOL in Children With Cystic Fibrosis

Not Applicable

• Conditions: Cystic Fibrosis in Children
• Interventions: Device: MyCyFAPP

• Registration Number: NCT03292718
• Lead Sponsor: Universitaire Ziekenhuizen KU Leuven

Brief Summary

Interventional trial to study the influence of the use of MyCyFAPP (mobile application) on the gastro-intestinal related quality of life.

This mobile APP has been developed during previous workpackages of the Horizon2020 Project and contains several modules:

* mathematical prediction model to calculate the needed dose for pancreatic enzyme replacement therapy

* educational games and other educational material

* communication with doctor/dietician through professional webtool

* diary to register symptoms and data on nutrition.

The app will be introduced and used during 6 months. Primary outcome parameter will be change in modified PedsQL GI after 3 months. PedsQL GI is an existing questionnaire that evaluates gastro-intestinal related quality of life in children. We validated it for use in cystic fibrosis in a previous observational study.

Detailed Description

Not available

Study Timeline

• Status Verified: 2017-09
• Study First Submitted: 2017-09-20
• Study First Submitted QC: 2017-09-20
• Last Update Submitted: 2017-09-20
• Study First Posted: 2017-09-25
• Last Update Posted: 2017-09-25
• Study Start: 2017-10
• Primary Completion: 2018-12
• Study Completion: 2018-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

1. Diagnosis of CF as evidenced by one or more clinical feature consistent with the CF phenotype or positive CF newborn screen AND one or more of the following criteria:

   1. A documented sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis (QPIT)
   2. A documented genotype with two disease-causing mutations in the CFTR gene

2. Having pancreatic insufficiency (stool elastase < 200 mcg/g stool) and using PERT

3. Age ≥ 24 months and < 18 years at screening visit

4. Informed consent by parent or legal guardian; assent for children from age 12 years on

5. Inclusion visit coincides with scheduled routine clinic visit 7. Ability and willingness to comply with APP use and evaluations at time of routine clinic visits as judged by the site investigator 8. Availability of wifi connection at home so that connection to the internet is feasible at home at least weekly.

Exclusion Criteria

1. Acute infection associated with decreased appetite or fever at time of run-in visit
2. Acute abdominal pain necessitating an intervention at time of run-in visit
3. Physical findings that would compromise the safety of the participant or the quality of the study data as determined by site investigator
4. Investigational drug use within 30 days prior to run-in visit
5. Started with CFTR modulator treatment less than 3 months before start of run-in visit
6. Inability to use the APP due to patient specific factors such as language or learning difficulties

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
use of MyCyFAPP	MyCyFAPP	use of MyCyFAPP during 6 months

Primary Outcome Measures

Name	Time	Method
change in Modified PedsQL GI	3 months	Modified PedsQL GI will be assessed at month 0 and month 3 by applying questionnaires to children and their parents

Secondary Outcome Measures

Name	Time	Method
change in Modified PedsQL GI	6 months	Modified PedsQL GI will be assessed at month 0 and month 6 by applying questionnaires to children and their parents
change in lung function	3 and 6 months	spirometry will be performed
change in CFQ-R	3 months and 6 months	CFQ-R will be assessed by questionnaires
change in VAS	3 months and 6 months	VAS will be assessed by questionnaires